4 completed, 1 recruiting. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Cowpox: new trials by email Literature Review of Cowpox trials Research Report on Cowpox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. BSY001 for Injection (37.5mg), BSY001 for Injection (75 mg), BSY001 for Injection (150 mg) - Smallpox, Cowpox | Phase 1 | Recruiting | China National Biotec Group Company Limited | 76 | 2025-08-28 | 2026-01-29 |
| Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years VAC∆6 vaccine (10⁷ PFU), VAC∆6 vaccine (10⁶ PFU), Live Smallpox Vaccine - Smallpox, Monkeypox | Phase 2 / Phase 3 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 334 | 2021-10-01 | 2023-05-06 |
| Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally, NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day), NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day) - Smallpox, Monkeypox | Phase 1 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 90 | 2020-09-04 | 2023-08-04 |
| Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years VAC∆6 vaccine - оnce at a dose of 10⁶ PFU, VAC∆6 vaccine - once at a dose of 10⁷ PFU, VAC∆6 vaccine - twice at a dose of 10⁶ PFU - Smallpox, Monkeypox | Phase 1 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 60 | 2019-05-18 | 2023-03-09 |
| Evaluation and Treatment of Eye Complications of Vaccinia Vaccination NP-016 Vaccine Immune Globulin (IV-VIG) - Vaccinia | Phase 2 | Completed | National Eye Institute (NEI) | 400 | 2004-04-19 | 2017-07-02 |
Smallpox (5) · Mpox, Monkeypox (4) · Conjunctivitis (1) · Corneal Diseases (1) · Corneal Ulcer (1) · Keratitis (1) · Poxviridae Infections (1) · Vaccinia (1)
DNA Virus Infections (5) · Infections (5) · Virus Diseases (5) · Animal Diseases (4) · Poxviridae Infections (4) · Primate Diseases (4) · Rodent Diseases (4) · Conjunctival Diseases (1) · Eye Diseases (1) · Eye Infections (1)
Injections (1) · NIOCH-14 (1) · Smallpox Vaccine (1)
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (3) · China National Biotec Group Company Limited (1) · National Eye Institute (NEI) (1)
Russia (3) · China (1) · United States (1)
Vladimir I. Kuzubov, PhD (3) · Irina V Krasil'nikova, PhD (1)